Shareholder Class Action for King Pharmaceuticals

We served as lead counsel for King Pharmaceuticals, Inc. and its board of directors in shareholder class actions relating to the $3.6 billion buyout of King by Pfizer, Inc.

King Pharmaceuticals (NYSE: KG) is a wholly owned subsidiary of Pfizer based in Bristol, Tennessee. Before being acquired by Pfizer, it was the world’s 39th largest pharmaceutical company.

You Also May Be Interested In:

  • Successfully represented AmSurg Holdings, Inc. in a dispute with a group of physicians seeking to invalidate a non-compete provision that was a material feature of a highly profitable surgery center partnership located in  Minnesota

    We represented AmSurg Holdings, Inc. in a dispute with a group of physicians seeking to invalidate a non-compete provision that...
    Client Type: Public Company
  • Representation of Triage Consulting Group, a healthcare revenue integrity company in its acquisition by Revint Solutions, a leader in technology-enabled revenue integrity solutions for healthcare providers

    We represented Triage Consulting Group, a healthcare revenue integrity company in its acquisition by Revint Solutions, a leader in technology-enabled...
    Client Type: Private Company
  • Representation of Twin River Worldwide Holdings, Inc. (NYSE: TRWH) in its definitive agreement to acquire Jumer’s Casino & Hotel, from Delaware North Companies Gaming & Entertainment, Inc., for $120 million in cash

     

    We represented Twin River Worldwide Holdings, Inc. in its definitive agreement to acquire Jumer's Casino & Hotel, from Delaware North...
    Client Type: Public Company